PreveCeutical Medical Inc.

PreveCeutical Announces Possible Viral Prevention Program Using CBD Sol-gel

PreveCeutical Retains Patent Legal Team

PreveCeutical Announces Further Updates to the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

PreveCeutical Announces Positive Results Following a Preliminary Safety Evaluation of Sol-Gel Formulations When Applied to Human Nasal Tissue

PreveCeutical Announces Successful Completion from its Design, Synthesis and Preliminary Evaluation of Novel Designed Peptides Derived from Caribbean Blue Scorpion Venom in a Cell-Based Brain Cancer Model

PreveCeutical Receives $616,802 AUD Research and Development Tax Incentive Cash Refund